UPDATE: Wedbush Color on Map Pharmaceuticals PT Increase

Wedbush, which raised its PT on shares of MAP Pharmaceuticals, Inc. MAPP, is providing some color on the stock. “The main concern investors have shared with us is safety since Levadex is orally-inhaled but not targeting a lung disease,” Wedbush writes. “Recall that Exubera (inhaled insulin) had delayed approval due to the impact on lung function. Levadex presentations at the American Headache Society's 53rd annual meeting (AHS June 2-5, 2011 Washington DC) continue to support a safety profile similar to placebo's impact on lung function.” MAP Pharmaceuticals closed Monday at $15.05.